| Literature DB >> 35408800 |
Anton Borger1,2, Sarah Stadlmayr1,2, Maximilian Haertinger1,2, Lorenz Semmler1,2, Paul Supper1,2, Flavia Millesi1,2, Christine Radtke1,2.
Abstract
A growing body of studies indicate that small noncoding RNAs, especially microRNAs (miRNA), play a crucial role in response to peripheral nerve injuries. During Wallerian degeneration and regeneration processes, they orchestrate several pathways, in particular the MAPK, AKT, and EGR2 (KROX20) pathways. Certain miRNAs show specific expression profiles upon a nerve lesion correlating with the subsequent nerve regeneration stages such as dedifferentiation and with migration of Schwann cells, uptake of debris, neurite outgrowth and finally remyelination of regenerated axons. This review highlights (a) the specific expression profiles of miRNAs upon a nerve lesion and (b) how miRNAs regulate nerve regeneration by acting on distinct pathways and linked proteins. Shedding light on the role of miRNAs associated with peripheral nerve regeneration will help researchers to better understand the molecular mechanisms and deliver targets for precision medicine.Entities:
Keywords: Schwann cell migration; Schwann cell proliferation; Wallerian degeneration; biomarker nerve injury; expression profile microRNA; mRNA nerve; myelination; pathway peripheral nerve; precision medicine; protein nerve
Mesh:
Substances:
Year: 2022 PMID: 35408800 PMCID: PMC8999002 DOI: 10.3390/ijms23073440
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Overview search algorithm and results.
List of identified miRNAs sorted by function.
| miR | Function | Effect | Target | Author, Year, Reference |
|---|---|---|---|---|
| miR-340 | Inflammation | Impair | TPA | Li et al. (2017), [ |
| miR-182 | Inflammation, Migration | Impair | FGF9, NTM | Yu et al. (2012), [ |
| miR-1 | Proliferation | Impair | BDNF | Yi et al. (2016), [ |
| miR-1b | Proliferation, Migration | Impair | NDRG3 | Liu et al. (2018), [ |
| miR-1b | Proliferation | Impair | KLF7 | Li et al. (2021), [ |
| miR-124 | Proliferation, Migration | Impair | STAT 3 | Nagata et al. (2014), [ |
| miR-21 | Proliferation | Promote | TGFb1, EPHA4, TIMP3 | Ning et al. (2020), [ |
| miR-21 | Proliferation | Promote | PTEN | Lopez-Leal et al. (2020), [ |
| miR-221/222 | Proliferation | Promote | LASS2 | Yu et al. (2012), [ |
| miR-221 | Myelination | Impair | NAB1 | Zhao et al. (2018), [ |
| miR-192 | Proliferation | Impair | XIAP | Liu et al. (2020), [ |
| miR-3099 | Proliferation, Migration | Promote | None identified | Liu et al. (2019), [ |
| miR-146b | Proliferation | Impair | KLF7 | Li et al. (2018), [ |
| miR-210 | Proliferation, Migration, Myelination | Promote proliferation and migration, impair myelination | None identified | Zhang et al. (2017), [ |
| miR-9 | Migration | Impair | CTHRC1 | Zhou et al. (2014), [ |
| miR-9/let-7 family | Migration | Impair | NTN1, DCC | Wang et al. (2019), [ |
| miR-138 | Migration | Impair | Vimentin | Sullivan et al. (2018), [ |
| miR-129 | Migration | Impair | IGF9 | Zhu et al. (2018), [ |
| miR-132 | Migration | Promote | PRKAG3 | Yao et al. (2016), [ |
| miR-3075 | Migration | Impair | CNTN2 | Wang et al. (2018), [ |
| miR-34a | Migration, Proliferation | Impair | CNTN2 | Zou et al. (2020), [ |
| miR-34a | Myelination, Proliferation | Promote myelination, Impair proliferation | NOTCH1, CCND1 | Viader et al. (2011), [ |
| miR-140 | Myelination | Impair | EGR2 | Viader et al. (2011), [ |
| Lin28/let-7-axis | Myelination | Promote | NOTCH1 | Gökbuget et al. (2018), [ |
| let-7 | Proliferation | Impair | NGF | Li et al. (2015), [ |
| miR-29a/miR-29b | Myelination | Impair | PMP22 | Verrier et al. (2009), [ |
| miR-485-5p | Myelination | Impair | CDC42, RAC1 | Zhang et al. (2020), [ |
| miR-30c | Myelination | Impair | MBP | Yi et al. (2017), [ |
Results for miRNA-expression profiles of miRNAs upon nerve lesion.
| Author, Year, Reference | Method | Species | Gender | Lesion Model | Time Points (Postinjury) |
|---|---|---|---|---|---|
| Viader et al. (2011), [ | Microarray | Mice | Both | Crush | 4 d, 14 d |
| Wu et al. (2011), [ | Microarray | Mice | Nd | Crush | 4 d, 7 d |
| Adilakshimi et al. (2012), [ | Microarray | Mice | Female | Cut | 6 h, 24 h |
| Yu et al. (2012), [ | Microarray | Rat | Male | Cut | 1 d, 4 d, 7 d, 14 d |
| Sullivan et al. (2018), [ | Microarray | Rat | Male | Cut | 30 d, 60 d, 70 d |
| Arthur-Farraj et al. (2017), [ | Illumina sequencing | Mice | Male | Cut | 3 d, 7 d |
| Yu et al. (2011), [ | Solexa sequencing | Rat | Male | Cut | 1 d, 4 d, 7 d, 14 d |
| Li et al. (2011), [ | Solexa sequencing | Rat | Male | Cut | 1 d, 4 d, 7 d, 14 d |
h = hours; d = days; Nd = not defined.
miRNA-expression profiles generated from literature search.
| Acute Phase | Late | |||||||
|---|---|---|---|---|---|---|---|---|
| miR | 6 h | 1 d | 4 d | 7 d | 14 d | 30 d | 60 d | 90 d |
| 182 | UP | DOWN | DOWN | NOT CLEAR | DOWN | DOWN | DOWN | |
| 340 | DOWN | DOWN | DOWN | NOT CLEAR | UP | UP | UP | |
| 132 | UP | UP | UP | UP | ||||
| 3075 | UP | UP | UP | UP | ||||
| 9 | DOWN | DOWN | DOWN | DOWN | DOWN | DOWN | DOWN | |
| 129 | NOT CLEAR | DOWN | DOWN | DOWN | UP | UP | UP | |
| 138 | DOWN | DOWN | DOWN | DOWN | DOWN | DOWN | DOWN | DOWN |
| 29a | NOT CLEAR | UP | UP | UP | ||||
| 29b | UP | UP | UP | UP | ||||
| 485 | UP | UP | NOT CLEAR | NOT CLEAR | ||||
| 30c | DOWN | DOWN | DOWN | DOWN | UP | |||
| 140 | DOWN | DOWN | DOWN | NOT CLEAR | UP | UP | UP | NORMAL |
| 34a | DOWN | DOWN | DOWN | DOWN | NOT CLEAR | |||
| let-7-a | DOWN | DOWN | DOWN | UP | NORMAL | UP | UP | |
| let-7-b | DOWN | DOWN | DOWN | UP | NORMAL | NORMAL | UP | |
| let-7-c | NORMAL | DOWN | DOWN | UP | ||||
| let-7-d | UP | DOWN | DOWN | UP | UP | UP | UP | |
| let-7-e | UP | DOWN | DOWN | UP | NORMAL | UP | UP | |
| let-7-f | NOT CLEAR | DOWN | DOWN | NORMAL | DOWN | NORMAL | UP | |
| 1 | DOWN | DOWN | DOWN | DOWN | DOWN | DOWN | NORMAL | |
| 124 | NOT CLEAR | DOWN | DOWN | DOWN | DOWN | DOWN | DOWN | |
| 192 | DOWN | DOWN | DOWN | NOT CLEAR | ||||
| 210 | DOWN | DOWN | DOWN | UP | ||||
| 146b | UP | UP | UP | UP | NOT CLEAR | UP | UP | UP |
| 21 | UP | UP | UP | UP | UP | UP | UP | |
| 221 | UP | UP | UP | UP | UP | UP | UP | |
| 222 | UP | DOWN | UP | UP | UP | UP | UP | |
| 3099 | UP | UP | NOT CLEAR | UP | ||||
In case of deviant literature conclusions, the results of the majority were taken. Results with no majority were defined as “NOT CLEAR” (in white). Upregulated miRNAs were marked green (“UP”); downregulated miRNAs red (“DOWN”); miRNA where no difference was found compared to healthy condition were defined as “NORMAL” (blue). If no data could be found for the corresponding time point and miRNA, the result was left blank; h = hours; d = days.
Figure 2Schematic overview of processes following peripheral nerve injury and accompanying miRNA expression patterns. Following peripheral nerve injury (a), Wallerian degeneration (b) occurs with a transdifferentiation of Schwann cells and inflammation. Subsequentially, Schwann cells align and start with building Bands of Büngner, supporting the axonal outgrowth through the lesion site (c). Finally, Schwann cells remyelinate the fresh-grown axons returning in their mature cell type (d). miRNAs and their respective targets subdivided in “inflammation”, “proliferation and migration”, and “myelination” overlap temporally in the stages “Wallerian Degeneration” (b) and “Schwann cell reorganization and axon outgrowth” (c).